Blood

Rapid preparation and application of a panel of clinical antibodies armed with B-BiTE for refractory malignancies

Tests could soon identify patients who will respond well to the available treatment for chronic myeloid leukaemia and those who will be resistant to it—which could improve their chances of survival.

Gene editing technology has been used to pinpoint new molecular targets for treating an aggressive form of leukemia in adults.

Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research’s (A*STAR’s) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression.